SRTOY (Sartorius Stedim Biotech) Total Current Assets: $1,908 Mil (As of Mar. 2026)


SRTOY Sartorius Stedim Biotech SA SRTOY
82 GF Score
Price $20.90
GF Value $23.61
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Sartorius Stedim Biotech Total Current Assets?

Sartorius Stedim Biotech SRTOY +2.20% 82 Total Current Assets is $1,908 Mil as of Mar. 2026. GuruFocus rates SRTOY with a GF Score™ of 82/100 and a GF Value™ of $23.61 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Sartorius Stedim Biotech's total current assets for the quarter that ended in Mar. 2026 was $1,908 Mil.


Sartorius Stedim Biotech  (OTCPK:SRTOY) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Sartorius Stedim Biotech's Liquidation Value for the quarter that ended in Mar. 2026 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=632.832-4678.382+0.75 * 301.04+0.5 * 826.243
=-3,407

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sartorius Stedim Biotech Total Current Assets Related Terms


Sartorius Stedim Biotech Total Current Assets Historical Data

* Premium members only.

The historical data trend for Sartorius Stedim Biotech's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sartorius Stedim Biotech Total Current Assets Chart

Sartorius Stedim Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,644.75 1,770.34 1,543.18 1,823.04 1,687.59

Sartorius Stedim Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,924.32 2,084.31 1,621.71 1,687.59 1,908.32
SRTOY
82GF Score
Sartorius Stedim Biotech SA SRTOY
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sartorius Stedim Biotech Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Sartorius Stedim Biotech's Total Current Assets for the fiscal year that ended in Dec. 2025 is calculated as

Sartorius Stedim Biotech's Total Current Assets for the quarter that ended in Mar. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of $1,908 Mil mean?
Sartorius Stedim Biotech (SRTOY) has a Total Current Assets of $1,908 Mil as of Mar. 2026. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Sartorius Stedim Biotech and its competitors.
Is Sartorius Stedim Biotech's Total Current Assets too high?
Sartorius Stedim Biotech's current Total Current Assets is $1,908 Mil. Overall, Sartorius Stedim Biotech has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Total Current Assets compare to ISRG and BDX?
Sartorius Stedim Biotech's Total Current Assets of $1,908 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Medical Devices & Instruments company?
A good Total Current Assets depends on the Medical Devices & Instruments industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Sartorius Stedim Biotech and its competitors. Sartorius Stedim Biotech's current Total Current Assets is $1,908 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (SRTOY) is currently considered Modestly Undervalued. The stock's GF Value™ is $23.61, compared to a current price of $20.90 — trading 11.5% below its estimated fair value. The current Total Current Assets is $1,908 Mil. Sartorius Stedim Biotech's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Sartorius Stedim Biotech (SRTOY), the current Total Current Assets is $1,908 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sartorius Stedim Biotech (SRTOY) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued. The current stock price of $20.90 is trading 11.5% below its estimated GF Value™ of $23.61. GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.

Key valuation signals for SRTOY:

  • Total Current Assets: $1,908 Mil
  • GF Value™: $23.61 vs. price of $20.90 (11.5% below fair value)
  • GF Score™: 82/100 with 5 warning signs

No single metric tells the full story. See the SRTOY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sartorius Stedim Biotech Business Description

Address Otto-Brenner-Strasse 20, Goettingen, DEU, 37079
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
82GF Score

Get the complete analysis for SRTOY

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.90
Price
$23.61
GF Value